Почетна › Рак на дојка › Мисури
Клинички испитувања за Рак на дојка во Мисури
75 студии за Рак на дојка бараат учесници на локации во Мисури.
Градови во Мисури
- St. Louis64 студии
- Kansas City34 студии
- Springfield10 студии
- Lee's Summit7 студии
- Saint Joseph7 студии
- Columbia6 студии
- O'Fallon6 студии
- Joplin4 студии
- Cape Girardeau4 студии
- Rolla3 студии
Официјален текст на студијата (англиски)
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- HCA Midwest Division, Kansas City
Се регрутираФаза 3
Возраст од 18 до 100 · Сите полови · Ажурирано 2.10.2026 · NCT05827081Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Oncology and Hematology - Clayton-Clarkson, Ballwin
- Central Care Cancer Center - Bolivar, Bolivar
- Cox Cancer Center Branson, Branson
- и уште 21
Се регрутираНабљудувачка студијаДобредојдени се здрави волонтери
Возраст од 40 до 75 · Сите полови · Ажурирано 2.10.2026 · NCT05334069A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Washington University, School of Medicine, St Louis
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 1.10.2026 · NCT06172478Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- St. Lukes Hospital of Kansas City, Kansas City
- Washington University School of Medicine, St Louis
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 1.10.2026 · NCT06625775A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- Missouri Cancer Associates, Columbia
- Saint Luke's Cancer Institute, Kansas City
- Oncology Hematology Associates, Springfield
- и уште 1
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 1.10.2026 · NCT06369285An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
- Washington University in St Louis, St Louis
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 28.9.2026 · NCT07222267A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Saint Luke's Cancer Institute ( Site 0059), Kansas City
- Washington University Siteman Cancer Center ( Site 0031), St Louis
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06966700A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Saint Luke's Cancer Institute ( Site 0027), Kansas City
- Washington University School of Medicine ( Site 0076), St Louis
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06312176A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, St Louis
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06103864ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- Washington University School of Medicine- Siteman Cancer Center, St Louis
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT07007559A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- Local Institution - 0140, St Louis
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 23.9.2026 · NCT06618287Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Kansas City
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 23.9.2026 · NCT07085767Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- Mercy Health - Sindelar Cancer Center, St Louis
- Mercy Health - Pratt Cancer Center, St Louis
Се регрутира
Возраст 18 и постари · Сите полови · Ажурирано 23.9.2026 · NCT07214532Cognitive Rehabilitation Following Breast Cancer Treatment
- University of Missouri, Columbia
Се регрутира
Возраст од 20 до 75 · Жени · Ажурирано 22.9.2026 · NCT06545045A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Saint Luke's Cancer Institute, Kansas City
- Oncology Hematology Associates, Springfield
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07174336A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Washington University, St Louis
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07114601A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- Washington University School of Medicine, St Louis
Се регрутираФаза 2
Возраст 18 и постари · Жени · Ажурирано 22.9.2026 · NCT07287098A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Washington University School of Medicine in St. Louis, St Louis
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07213791ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- Saint Luke's Hospital of Kansas City, Kansas City
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 17.9.2026 · NCT07173751A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Washington Univ. School of Medicine, St Louis
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 17.9.2026 · NCT07109726A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
- Saint Luke's Hospital of Kansas City, Kansas City
- Washington University School of Medicine, St Louis
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 17.9.2026 · NCT06827236Precision Supplemental Imaging in Women With Dense Breasts
- Washington University School of Medicine, St Louis
Се регрутираДобредојдени се здрави волонтери
Возраст од 25 до 55 · Жени · Ажурирано 16.9.2026 · NCT07277738A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Siteman Cancer Center, St Louis
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 15.9.2026 · NCT06492616A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, St Louis
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 11.9.2026 · NCT05123482A Phase 1/1b Study of IAM1363 in HER2 Cancers
- Saint Luke's Cancer Institute, Kansas City
- Washington University School of Medicine, St Louis
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 9.9.2026 · NCT06253871A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
- Washington University School of Medicine, St Louis
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 9.9.2026 · NCT06440005A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
- Washington University Medical School, St Louis
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 8.9.2026 · NCT05307705A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- Washington University Siteman Cancer Center, St Louis
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 8.9.2026 · NCT07100106To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
- HCA Midwest Division, Kansas City
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 4.9.2026 · NCT07368998Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Washington University School of Medicine- Siteman Cancer Center, St Louis
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 3.9.2026 · NCT06982521Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Oncology Hematology Associates, Springfield
Се регрутираНабљудувачка студија
Возраст од 18 до 99 · Сите полови · Ажурирано 3.9.2026 · NCT07211178A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- HCA Midwest Health, Kansas City
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 3.9.2026 · NCT06790693Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women
- Washington University School of Medicine, St Louis
Се регрутираНабљудувачка студија
Возраст од 18 до 50 · Жени · Ажурирано 2.9.2026 · NCT06904365The Vanguard Study: Testing a New Way to Screen for Cancer
- Saint Luke's Hospital of Kansas City, Kansas City
- Washington University School of Medicine, St Louis
Се регрутираДобредојдени се здрави волонтери
Возраст од 45 до 75 · Сите полови · Ажурирано 2.9.2026 · NCT06995898Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Mercy Oncology and Hematology - Clayton-Clarkson, Ballwin
- Central Care Cancer Center - Bolivar, Bolivar
- Cox Cancer Center Branson, Branson
- и уште 29
Се регрутираФаза 3
Возраст од 18 до 60 · Жени · Ажурирано 2.9.2026 · NCT05879926A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- Washington University, St Louis
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 28.8.2026 · NCT07029399Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
- WA Uni School Of Med, St Louis
Се регрутираФаза 1/2
Возраст од 18 до 100 · Сите полови · Ажурирано 27.8.2026 · NCT06726148A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
- Washington University School of Medicine - Siteman Cancer Center, St Louis
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 26.8.2026 · NCT07383506A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Washington University, Siteman Cancer Center, St Louis
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 21.8.2026 · NCT06774963Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
- Universtiy Health, Kansas City
- KCCC South, Kansas City
- Research Medical Center, Kansas City
- и уште 2
Се регрутираНабљудувачка студијаДобредојдени се здрави волонтери
Сите возрасти · Сите полови · Ажурирано 18.8.2026 · NCT02302742Од ClinicalTrials.gov, податоци преземени 5.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.